SC1 is a dual function small molecule inhibitor of both ERK1 and RasGAP and that simultaneous inhibition of both protein activities is required and sufficient for SC1’s effects on mES cells. SC1 activates Ras by inhibition of RasGAP function. SC1 improved the derivation efficiency and pluripotency of ES cells from C57BL/6. Three types of pluripotent stem cells (fES, ntES, and iPS cells) of the C57BL/6 background could generate full-term pups with high efficiency when cultured with SC1.
|Cell lines||Mouse ES cells|
|Preparation method||mES cells are seeded in gelatin-coated six-well plates at 1.6×104 cells/cm2 and maintained with 3 μM SC1 in ESC-SR media, 1 μM SC1 in ESC-N2B27 media, or 300 nM SC1 in ESC-N2 media without LIF or feeder cells. mES cells maintained with 103 units/ml LIF plus 10 ng/ml BMP4 in ESC-N2B27 media are used as a positive control. mES cells treated with DMSO in ESC-SR media, ESC-N2B27 media, or ESC-N2 media for two passages are used as negative controls. Cells are split every 3 days and seeded at same density (1.6×104 cells/cm2). mES cells at passage 11 are analyzed with FACS, immunocytochemistry, histocytochemistry, and RT-PCR.|
|Concentrations||300 nM, 1 μM, 3 μM|
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.
|Solubility||100 mg/mL in DMSO|
A small molecule (pluripotin) as a tool for studying cancer stem cell biology: proof of concept.
Mertins SD, et al. PLoS One. 2013;8(2):e57099. PMID: 23437320.
Oct4 and the small molecule inhibitor, SC1, regulates Tet2 expression in mouse embryonic stem cells.
Wu Y, et al. Mol Biol Rep. 2013 Apr;40(4):2897-906. PMID: 23254757.
|Related ERK Products|
VX-11e is a potent, selective, and orally bioavailable ERK2 inhibitor with Ki of <2 nM, over 200-fold selective over other kinases tested.
XMD8-92 is a potent and selective BMK1/ERK5 inhibitor with Kd of 80 nM.
VRT752271 (BVD-523, Ulixertinib) is a potent and reversible ERK1/ERK2 inhibitor with IC50 of <0.3 nM for ERK2. Phase 1.
DEL-22379 is a water-soluble ERK dimerization inhibitor with IC50 of ∼0.5 μM.
XMD17-109 is a novel, specific inhibitor of ERK-5 with an EC50 value of 4.2 μM in HEK293 cells.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.